|

Icaritin Clinical Trials

2 actively recruiting trials

Pipeline

Phase 3: 1

Top Sponsors

  • Nanjing Tianyinshan Hospital1
  • Beijing Shenogen Biomedical Co., Ltd1

Indications

  • Liver Disease2
  • Liver Cancer2
  • Cancer2
  • Hepatocellular Carcinoma (HCC)1
  • Hepatocellular Carcinoma1

Other2 trials

Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)
Phase 3
Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma
N/A

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.